Barbalho Cilene Aparecida, Nunes-de-Souza Ricardo L, Canto-de-Souza Azair
Grupo de Psicobiologia/Depto de Psicologia/CECH - UFSCar, Rod. Washington Luís, Km 235, 13565-905 São Carlos, SP, Brazil.
Brain Res. 2009 Apr 24;1267:65-76. doi: 10.1016/j.brainres.2009.02.042. Epub 2009 Mar 5.
Previous studies have demonstrated that microinjections of midazolam, a benzodiazepine receptor agonist, into the amygdala produce anxiolytic-like effects in elevated plus-maze (EPM)-naïve rodents. However, systemic or intracerebral administration of benzodiazepines (BDZ) fails to alter anxiety in maze-experienced animals, a phenomenon defined as "one trial tolerance" (OTT). This study focused on the effects of intra-amygdala infusion of midazolam in maze-experienced mice. In addition, the effects of flumazenil in the amygdala of maze-naïve and experienced mice were also investigated. To investigate intrinsic effects of intra-amygdala flumazenil on anxiety, animals were systemically treated with the BDZ receptor inverse agonist, DMCM (4-ethyl-6,7-dimethoxy-9H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester hydrochloride). Conventional measures of anxiety (% open arm entries and % open arm time), locomotor activity (frequency of closed arm entries) and a range of ethological measures related to risk assessment were recorded. Intra-amygdala midazolam (3.0 and 30 nmol) attenuated anxiety in maze-experienced mice. A similar behavioral profile was produced by intra-amygdala flumazenil in maze-naïve (4.0 and 16 nmol) and maze-experienced (16 nmol) mice. Intra-amygdala flumazenil (at 2.0 nmol, a dose devoid of any intrinsic effect on anxiety measures in the EPM) selectively and completely blocked the anxiogenic-like effects of systemic administration of DMCM (1.0 mg/kg, i.p.) in maze-naïve mice. Together, these results demonstrate that the GABA(A)-benzodiazepine receptor complex located within the amygdala does not play a role in the OTT phenomenon. Present results also suggest that the release of an endogenous BDZ receptor inverse agonist within the amygdala seems to be an important correlate of the emotional state induced by the plus-maze test.
先前的研究表明,向杏仁核微量注射苯二氮䓬受体激动剂咪达唑仑,可在未接触过高台十字迷宫(EPM)的啮齿动物中产生抗焦虑样效应。然而,全身或脑内给予苯二氮䓬(BDZ)并不能改变有迷宫经验动物的焦虑状态,这一现象被定义为“单次试验耐受”(OTT)。本研究聚焦于向有迷宫经验的小鼠杏仁核内注射咪达唑仑的效应。此外,还研究了氟马西尼对未接触迷宫和有迷宫经验小鼠杏仁核的影响。为研究杏仁核内注射氟马西尼对焦虑的内在影响,动物接受了BDZ受体反向激动剂DMCM(4-乙基-6,7-二甲氧基-9H-吡啶并[3,4-b]吲哚-3-羧酸甲酯盐酸盐)的全身治疗。记录了焦虑的常规指标(开放臂进入百分比和开放臂停留时间百分比)、运动活动(封闭臂进入频率)以及一系列与风险评估相关的行为学指标。杏仁核内注射咪达唑仑(3.0和30 nmol)可减轻有迷宫经验小鼠的焦虑。杏仁核内注射氟马西尼在未接触迷宫(4.0和16 nmol)和有迷宫经验(16 nmol)的小鼠中产生了类似的行为表现。杏仁核内注射氟马西尼(2.0 nmol,该剂量对EPM中的焦虑指标无任何内在影响)选择性且完全阻断了未接触迷宫小鼠全身注射DMCM(1.0 mg/kg,腹腔注射)产生的致焦虑样效应。总之,这些结果表明,位于杏仁核内的GABA(A)-苯二氮䓬受体复合物在OTT现象中不起作用。目前的结果还表明,杏仁核内内源性BDZ受体反向激动剂的释放似乎是由十字迷宫试验诱导的情绪状态的重要相关因素。